Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Moderna, Inc. Director's Dealing 2026

Mar 3, 2026

30610_dirs_2026-03-03_e71edc3f-e291-4ca5-8cdf-9351c3458cf1.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2026-02-27

Reporting Person: Mock James M (Chief Financial Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2026-02-27 Common Stock M 329 Acquired 45553 Direct
2026-02-27 Common Stock F 160 $51.71 Disposed 45393 Direct
2026-02-27 Common Stock M 774 Acquired 46167 Direct
2026-02-27 Common Stock F 375 $51.71 Disposed 45792 Direct
2026-02-27 Common Stock M 9901 Acquired 55693 Direct
2026-02-27 Common Stock F 4788 $51.71 Disposed 50905 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2026-02-27 Restricted Stock Units $ M 329 Disposed Common Stock (329) Direct
2026-02-27 Restricted Stock Units $ M 774 Disposed Common Stock (774) Direct
2026-02-27 Restricted Stock Units $ M 9901 Disposed Common Stock (9901) Direct
2026-03-01 Stock Option (Right to Buy) $53.57 A 37639 Acquired 2036-03-01 Common Stock (37639) Direct
2026-03-01 Restricted Stock Units $ A 49569 Acquired Common Stock (49569) Direct

Footnotes

F1: Restricted stock units convert into common stock on a one-for-one basis.

F2: Represents shares withheld at the election of the Reporting Person to satisfy tax withholding obligations in connection with the vest of restricted stock units.

F3: 25% of the shares subject to this restricted stock unit award vested on February 28, 2024 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

F4: 25% of the shares subject to this restricted stock unit award vested on February 27, 2025 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

F5: 25% of the shares subject to this restricted stock unit award vested on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

F6: 25% of this option will vest and become exercisable on March 1, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

F7: 25% of the shares subject to this restricted stock unit award will vest on March 1, 2027 with the remainder vesting in twelve (12) equal quarterly installments thereafter.